We examined expression of HER2, p53, and Ki67 in primary invasive breast carcinomas by IHC from 73 patients with metastatic breast cancer who received endocrine therapy as first-line treatment on relapse (Figure 1). The gene discussed is TP53; the disease is invasive breast carcinoma.